Skip to main content

Table 1 Patient demographics

From: High expression of TAZ indicates a poor prognosis in retinoblastoma

Characteristic No. of patients n = 43, n (%)
Patients 43 (100)
Age at presentation (y)  
  < 5 y 39 (90.7)
  ≥ 5 y 4 (9.3)
Gender  
 Male 18 (41.9)
 Female 25 (58.1)
Hereditary pattern  
 Sporadic 42 (97.7)
 Familial 1 (2.3)
Laterality  
 Unilateral 34 (79.1)
 Bilateral 9 (20.9)
Unilateral (n = 34)  
 Right 21 (61.8)
 Left 13 (38.2)
First clinical presenting signs  
 Leucocoria 34 (79.1)
 Strabismus 5 (11.6)
 Proptosis 3 (7.0)
 Swelling 1 (2.3)
cTNM clinical classification  
 T classification  
 T1 10 (23.3)
 T2 14 (32.6)
 T3 11 (25.6)
 T4 8 (18.6)
N classification  
 N0 20 (46.5)
 N1 17 (39.5)
 N2 6 (14.0)
M classification  
 M0 31 (72.1)
 M1 12 (27.9)
cTNM stage  
 I 2 (4.7)
 II 12 (27.9)
 III 17 (39.5)
 IV 12 (27.9)
Largest tumor base (mm), mean (median, range) 11.3 (5–26)
  ≤ 15 mm 28 (58.1)
  > 15 mm 15 (41.9)
Tumor thickness (mm), mean (median, range) 8.6 (9, 3–16)
  ≤ 10 mm 25 (58.1)
  > 10 mm 18 (41.9)
Growth pattern  
 Endophytic 12 (27.9)
 Exophytic 20 (46.5)
 Mixed 5 (11.6)
 Diffuse infiltrating 6 (14.0)
Differentiation  
 Well 9 (20.9)
 Moderate 15 (34.9)
 Poorly 19 (44.2)
Treatment  
 Eye enucleated 19 (44.2)
 Enucleated + chemotherapy 22 (51.2)
 Enucleated + chemotherapy + radiation therapy 2 (4.7)
Outcomes  
 Death 14 (32.6)
 Survival 29 (67.4)